Roswell Park Experts Share Latest Hematology Research at 67th ASH Annual Meeting

BUFFALO, N.Y. — Experts from Roswell Park Comprehensive Cancer Center will discuss their latest discoveries at the 67th annual meeting of the American Society of Hematology (ASH) December 6-9 in Orlando, Florida. Every year, more than 30,000 attendees from around the world gather at this prestigious meeting to learn about emerging treatments and other important advances in the field. Members of the Roswell Park team have been invited to present their work on cellular therapy, targeted therapy and other aspects of treating hematological malignancies, or blood cancers.

“Roswell Park has a comprehensive presence at ASH 2025, showcasing expertise across the hematologic malignancies and cell therapy. From the Satellite Symposium to the individual abstract presentations, Roswell Park is driving innovation for cancer patients, and we are proud to be part of this important exchange with our colleagues across the world,” says Brian Betts, MD, a hematologist-oncologist who is Vice Chair of Strategic Initiatives focused on transplant and cellular therapy.

Oral abstract presentations

Four oral abstract sessions during the meeting will showcase work led by Roswell Park experts.

Sunday, Dec. 7

• Meredith Stone, PhD, is presenting author, with senior author Marco Davila, MD, PhD, on oral abstract 13711, CAR T cell-driven induction of iNOS in tumor associated macrophages promotes CAR T cell resistance in B cell lymphoma. Sunday, Dec. 7, 1:15-1:30 p.m. EST in Tangerine Ballroom F1.

Monday, Dec. 8

• Eunice Wang, MD, is senior author on abstract 7396, Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial; presenting author is Thomas Cluzeau, MD, PhD, of Centre Hospitalier Universitaire de Nice. Monday, Dec. 8, 11:30-11:45 a.m. EST in Chapin Theater, W320.

• Eunice Wang, MD, is senior author on abstract 3910, Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET007; presenting author is Amir Fathi, MD, of Massachusetts General Hospital/Dana-Farber Harvard Cancer Center. Monday, Dec. 8, 11:45 a.m.-noon EST in Chapin Theater, W320.

• Megan Herr, PhD, is first/presenting author, with senior author Theresa Hahn, PhD, on oral abstract 8885, Overall survival after post-transplant cyclophosphamide (PTCy) peripheral blood hematopoietic cell transplantation (HCT) differs by race, ethnicity, and donor. Monday, Dec. 8, 3:15-3:30 p.m. EST in W414C.

Satellite Symposium Friday

Roswell Park is hosting the satellite symposium “Bridging the Gaps in Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access,” co-chaired by Marco Davila, MD, PhD, and Renier Brentjens, MD, PhD, on Friday, Dec. 5, 202, from 3-6 p.m. EST.

Chimeric antigen receptor (CAR) T-cell therapy has reshaped the treatment landscape for lymphoid and myeloid malignancies, yet major clinical and implementation challenges persist. This symposium addresses critical unmet needs in the field, including optimization of CAR T cells in real-world practice, managing post-relapse scenarios and expanding access to underserved populations. Speakers:

• Shernan Holtan, MD, Professor of Medicine and Chief of Blood and Marrow Transplant, Roswell Park

• Francisco Hernandez-Ilizaliturri, MD, Professor of Oncology and Director of Lymphoma Research, Roswell Park

• Julio Chavez, MD, MS, Senior Associate Consultant and Lymphoma Program Lead, Mayo Clinic–Jacksonville

• Frederick Locke, MD, Chair of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center

For more information or to register for the virtual symposium, go to roswellpark.org/ASH.

Moderators and awards

• Ehsan Malek, MD, will moderate oral abstract session 907, Outcomes Research: Plasma Cell Disorders: Innovations in Myeloma: Therapy, Prevention & Patient-Centered Care, Saturday, Dec. 6, 4-5:30 p.m. EST in  West Hall E2.

• Rohit Gosain, MD, will co-host Advancements in Oncology – Today’s Data for Tomorrow’s Practice, Sunday, Dec. 7, 2025, from 7-9 p.m. EST at Del Frisco’s Double Eagle, 9150 International Drive, Orlando,

• Pamela Sung, MD, PhD, will moderate oral abstract session 604, Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms - Novel Targets and Drugs, Monday, Dec. 8, 10:30 a.m.-noon in the Valencia Room, W415BC.

• Eunice Wang, MD, will be the featured speaker at an educational session, The Promise of Menin Inhibitors: From Approval to Triplet Regimens, Monday, Dec. 8, 10:50-11:10 a.m. EST in room W414CD.

• Six experts representing Roswell Park and the University at Buffalo Jacobs School of Medicine and Biomedical Sciences earned ASH abstract Achievement Awards for work to be presented during the meeting: Resident Physician Nour Nassour, MD, fellows Anuja Abhyankar, MD, Ross McCauley, MD, Allan Pavy, PhD, and Rahul Thakur, MD, and predoctoral trainee Jacob Wright. 

Additional presentations

Also sharing new findings during ASH 2025 are the following Roswell Park experts:

Saturday, Dec. 6

• Ehsan Malek, MD, is first/presenting author on abstract 11278, Unstructured serum electrophoresis data limits real-world AI models in multiple myeloma: Evaluation of 384 institutions across United States, Saturday, Dec. 6, 5:30-7:30 p.m. EST in West Halls B3-B4

• Ehsan Malek, MD, is first/presenting author on abstract 11347, Race agnostic models maintain accuracy in predicting m-protein levels in multiple myeloma, Saturday, Dec. 6, 5:30-7:30 p.m. EST in West Halls B3-B4

• Theresa Hahn, PhD, is first/presenting author on abstract 11153, Pre-HCT creatinine defines sex-specific risk for severe TMA after allogeneic transplantation: A report from the MIDAS consortium, Saturday, Dec. 6, 5:30-7:30 p.m. EST in West Halls B3-B4

• Jens Hillengass, MD, PhD, is senior/presenting author, with first author Janine Joseph, MS, MBA, on abstract 14670, Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders, Saturday, Dec. 6, 5:30-7:30 p.m. EST in West Halls B3-B4

• Ross McCauley, MD, is first/presenting author on abstract 13552, CRS/ICANS prophylaxis does not improve outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel, Saturday, Dec. 6, 5:30-7:30 p.m. EST in West Halls B3-B4

• Murugan Selvam, PhD, is first/presenting author, with senior author Pamela Sung, MD, PhD, on abstract 1911, Combined FLT3 and EZH1/2 inhibition reduces LSCs and promoted myeloid differentiation in PDX models of AML, Saturday, Dec. 6, 5:30-7:30 p.m. EST in West Halls B3-B4. Funding for this work was provided through the Roswell Park Alliance Foundation and the ASH Scholar Award.

• Rabsa Sikder is first author, with senior author Song Yao, MD, PhD, on abstract 1544, Age at diagnosis drives molecular pathology and prognosis in diffuse large B-cell lymphoma, Saturday, Dec. 6, 5:30-7:30 p.m. EST in West Halls B3-B4

Sunday, Dec. 7

• Anuja Abhyankar, MD, is senior/presenting author on abstract 12420, Real-world comparative effectiveness of quadruplet vs. triplet induction in multiple myeloma, Sunday, Dec. 7, 6-8 p.m. EST in West Halls B3-B4. 

• Marco Davila, MD, PhD, is senior/presenting author, with first author Brian Betts, MD, on abstract 1897, CD83 CAR T overcome CD19 antigen loss in B-cell malignancies after CD19-directed therapy, Sunday, Dec. 7, 6-8 p.m. EST in West Halls B3-B4

• Marco Davila, MD, PhD, is senior/presenting author, with first author Min Ma, MD, on abstract 2219, In-depth, quantitative characterization of important regulators and predictive biomarkers for CAR T-cell therapy induced toxicities in a clinical cohort, Sunday, Dec. 7, 6-8 p.m. EST in West Halls B3-B4

• Ehsan Malek, MD, is first/presenting author on abstract 11165, Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling, Sunday, Dec. 7, 6-8 p.m. EST in West Halls B3-B4

• Ehsan Malek, MD, is senior/presenting author, with first author Rahul Thakur, MD, on abstract 4075, Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant, Sunday, Dec. 7, 6-8 p.m. EST in West Halls B3-B4

• Leslie Martinez-Gutierrez, MS, is first/presenting author, with senior author Eunice Wang, MD, on abstract 9762, PARP inhibition by talazoparib results in leukemia cell death via induction of myeloid differentiation, Sunday, Dec. 7, 6-8 p.m. EST in West Halls B3-B4

• Nour Nassour, MD, is first/presenting author, with co-senior authors Philip McCarthy, MD, and Hemn Mohammadpour, DVM, PhD, on abstract 7910, Galectin-3 in host murine models lessens severity of graft-versus-host disease by preserving intestinal stem cells irrespective of gut microbiota composition, Sunday, Dec. 7, 6-8 p.m. EST in West Halls B3-B4. 

• Alex Niu, MD, is first/presenting author, with senior author Francisco Hernandez-Ilizaliturri, MD, on abstract 9628, Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers, Sunday, Dec. 7, 6-8 p.m. in West Halls B3-B4

• Rahul Thakur, MD, is first/presenting author, with senior authors Francisco Hernandez-Ilizaliturri, MD, and Alex Niu, MD, on abstract 7358, Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubucin (R+DA+EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience, Sunday, Dec. 7, 6-8 p.m. EST in West Halls B3-B4

• Eunice Wang, MD, is senior/presenting author on abstract 2246, Analysis of hematologic improvement (HI) by time to response in relapsed/refractory acute myeloid leukemia (AML) patients treated with olutasidenib, Sunday, Dec. 7, 6-8 p.m. in West Halls B3-B4

Monday, Dec. 8

• Sawyer Bawek, MD, is first/presenting author, with co-senior authors Megan Herr, PhD, and Jens Hillengass, MD, PhD,  on abstract 14319, Impact of pre-transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation, Monday, Dec. 8, 6-8 p.m. EST in West Halls B3-B4

• Ajinkya Buradkar, MD, is first/presenting author and Francisco Hernandez-Ilizaliturri, MD, is senior author on abstract 15602, Impact of apheresis-to-infusion interval on outcomes and toxicity of CAR T therapy in relapsed/refractory DLBCL, Monday, Dec. 8, 6-8 p.m. EST in West Halls B3-B4

• Philip McCarthy, MD, is presenting author, with first author Janine Joseph, MS, MBA, and senior author Jens Hillengass, MD, PhD, on abstract 14567, Circulating immune profile in patients with amyloidosis, Monday, Dec. 8, 6-8 p.m. EST in West Halls B3-B4

• Allan Pavy, PhD, is first/presenting author, with senior author Marco Davila, MD, PhD, on abstract 7239, IL-2 mutein-mediated improvement of CAR T function in relapsed/refractory diffuse B-Cell lymphoma, Monday, Dec. 8, 6-8 p.m. EST in West Halls B3-B4

• Rahul Thakur, MD, is first/presenting author, with senior author Eunice Wang, MD, on abstract 4133, Machine learning accurately predicts mortality in adult NPM1-mutant acute myeloid leukemia using baseline clinical and genomic features, Monday, Dec. 8, 6-8 p.m. EST in West Halls B3-B4

• Jacob Wright is first/presenting author, with senior authors Matthew Cortese, MD, MPH, and Spencer Rosario, PhD, on abstract 5661, Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CAR T) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL), Monday, Dec. 8, 6-8 p.m. EST in West Halls B3-B4

• Eunice Wang, MD, is first/presenting author on abstract 5221, Favorable Outcomes Including Post-Transplant Survival Are Seen Independent of Baseline Skin Burden in Treatment-Naϊve Patients (Pts) with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Tagraxofusp (TAG): Subgroup Analysis of a Pivotal Trial, Monday, Dec. 8, 6-8 p.m. EST in West Halls B3-B4
   

###
 

From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. The Roswell Park team of 4,000+ makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Rated “Exceptional” by the National Cancer Institute, Roswell Park, founded in 1898, was one of the first NCI-designated comprehensive cancer centers in the country and remains the only one in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.